Liver Fibrosis - Pipeline Review, H2 2016

Liver Fibrosis - Pipeline Review, H2 2016


  • Products Id :- GMDHC8453IDB
  • |
  • Pages: 199
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Liver Fibrosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Liver Fibrosis - Pipeline Review, H2 2016', provides an overview of the Liver Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis

- The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects

- The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Liver Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Liver Fibrosis Overview 9

Therapeutics Development 10

Pipeline Products for Liver Fibrosis - Overview 10

Pipeline Products for Liver Fibrosis - Comparative Analysis 11

Liver Fibrosis - Therapeutics under Development by Companies 12

Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes 15

Liver Fibrosis - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Liver Fibrosis - Products under Development by Companies 18

Liver Fibrosis - Products under Investigation by Universities/Institutes 22

Liver Fibrosis - Companies Involved in Therapeutics Development 23

Advinus Therapeutics Ltd 23

Akarna Therapeutics Ltd. 24

Angion Biomedica Corp. 25

Asubio Pharma Co., Ltd. 26

aTyr Pharma, Inc. 27

Beijing Kawin Technology Share-Holding Co., Ltd. 28

BioLineRx, Ltd. 29

Bioneer Corporation 30

BiOrion Technologies B.V. 31

Bird Rock Bio, Inc. 32

Bristol-Myers Squibb Company 33

Cellmid Limited 34

ContraVir Pharmaceuticals, Inc. 35

Dicerna Pharmaceuticals, Inc. 36

Digna Biotech, S.L. 37

Dr. Falk Pharma GmbH 38

Dynavax Technologies Corporation 39

Evotec AG 40

Galectin Therapeutics, Inc. 41

Genfit SA 42

Gilead Sciences, Inc. 43

GNI Group Ltd. 44

HEC Pharm Co., Ltd. 45

Immuron Limited 46

Intercept Pharmaceuticals, Inc. 47

INVENT Pharmaceuticals, Inc. 48

Isarna Therapeutics GmbH 49

KineMed, Inc. 50

LG Life Science LTD. 51

Nitto Denko Corporation 52

Pfizer Inc. 53

Pharmaxis Limited 54

Promedior, Inc. 55

Promethera Biosciences S.A. 56

ProMetic Life Sciences Inc. 57

Ribomic Inc. 58

RXi Pharmaceuticals Corporation 59

Silence Therapeutics Plc 60

TCM Biotech International Corp 61

Vascular Biogenics Ltd. 62

Virobay Inc. 63

XTuit Pharmaceuticals, Inc. 64

Liver Fibrosis - Therapeutics Assessment 65

Assessment by Monotherapy Products 65

Assessment by Combination Products 66

Assessment by Target 67

Assessment by Mechanism of Action 71

Assessment by Route of Administration 74

Assessment by Molecule Type 76

Drug Profiles 78

ANG-3070 - Drug Profile 78

ANG-3281 - Drug Profile 79

Antisense RNAi Oligonucleotide for Liver Disease - Drug Profile 80

Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile 81

Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 82

Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 83

Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 84

Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile 85

Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis - Drug Profile 86

ASB-14780 - Drug Profile 87

BL-1210 - Drug Profile 88

BMS-986171 - Drug Profile 89

BOT-162 - Drug Profile 90

BOT-191 - Drug Profile 91

CAB-102 - Drug Profile 92

CPI-43132 - Drug Profile 94

CT-140 - Drug Profile 97

DB-036 - Drug Profile 98

Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile 99

Drugs for Tissue Fibrosis - Drug Profile 100

DV-1079 - Drug Profile 101

F-351 - Drug Profile 103

Gene Therapy for Liver Fibrosis - Drug Profile 105

GMCT-01 - Drug Profile 106

GRMD-02 - Drug Profile 110

GS-444217 - Drug Profile 121

HEC-585 - Drug Profile 122

HepaStem - Drug Profile 123

IMM-124E - Drug Profile 125

INT-767 - Drug Profile 128

INV-240 - Drug Profile 129

ISTH-0047 - Drug Profile 130

KW-0 - Drug Profile 132

KW-012 - Drug Profile 133

LC-280126 - Drug Profile 134

melittin - Drug Profile 135

Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Fibrosis - Drug Profile 136

MOR-8457 - Drug Profile 137

MRI-1867 - Drug Profile 138

ND-L02s0201 - Drug Profile 139

norursodeoxycholic acid - Drug Profile 141

noscapine - Drug Profile 142

PBI-4050 - Drug Profile 143

PRM-151 - Drug Profile 148

Proteins for Liver Fibrosis - Drug Profile 153

PXS-4820 - Drug Profile 154

PXS-5033A - Drug Profile 155

RBM-006 - Drug Profile 156

Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile 157

RXI-209 - Drug Profile 158

RYI-018 - Drug Profile 159

selonsertib - Drug Profile 160

selonsertib + simtuzumab - Drug Profile 161

Small Molecule for Liver Fibrosis - Drug Profile 162

Small Molecule for Liver Fibrosis - Drug Profile 163

Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile 164

Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 165

Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile 166

Small Molecules for Hepatic Fibrosis - Drug Profile 167

Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 168

Stem Cell Therapy for Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile 169

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile 170

TCM-808FB - Drug Profile 171

TGFTX-4 - Drug Profile 172

VB-201 - Drug Profile 173

VB-703 - Drug Profile 176

VBY-376 - Drug Profile 177

VBY-825 - Drug Profile 178

Liver Fibrosis - Dormant Projects 179

Liver Fibrosis - Discontinued Products 183

Liver Fibrosis - Product Development Milestones 184

Featured News & Press Releases 184

Appendix 193

Methodology 193

Coverage 193

Secondary Research 193

Primary Research 193

Expert Panel Validation 193

Contact Us 193

Disclaimer 194

List of Figures

Number of Products under Development for Liver Fibrosis, H2 2016 15

Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 70

Number of Products by Top 10 Targets, H2 2016 72

Number of Products by Stage and Top 10 Targets, H2 2016 72

Number of Products by Top 10 Mechanism of Actions, H2 2016 76

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 76

Number of Products by Routes of Administration, H2 2016 79

Number of Products by Stage and Routes of Administration, H2 2016 79

Number of Products by Top 10 Molecule Types, H2 2016 81

Number of Products by Stage and Top 10 Molecule Types, H2 2016 81

List of Tables

Number of Products under Development for Liver Fibrosis, H2 2016 15

Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Development by Companies, H2 2016 (Contd..3) 26

Products under Investigation by Universities/Institutes, H2 2016 27

Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016 28

Liver Fibrosis - Pipeline by Akarna Therapeutics Ltd., H2 2016 29

Liver Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016 30

Liver Fibrosis - Pipeline by Asubio Pharma Co., Ltd., H2 2016 31

Liver Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016 32

Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016 33

Liver Fibrosis - Pipeline by BioLineRx, Ltd., H2 2016 34

Liver Fibrosis - Pipeline by Bioneer Corporation, H2 2016 35

Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016 36

Liver Fibrosis - Pipeline by Bird Rock Bio, Inc., H2 2016 37

Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 38

Liver Fibrosis - Pipeline by Cellmid Limited, H2 2016 39

Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 40

Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016 41

Liver Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016 42

Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H2 2016 43

Liver Fibrosis - Pipeline by Dynavax Technologies Corporation, H2 2016 44

Liver Fibrosis - Pipeline by Evotec AG, H2 2016 45

Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016 46

Liver Fibrosis - Pipeline by Genfit SA, H2 2016 47

Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2016 48

Liver Fibrosis - Pipeline by GNI Group Ltd., H2 2016 49

Liver Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016 50

Liver Fibrosis - Pipeline by Immuron Limited, H2 2016 51

Liver Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 52

Liver Fibrosis - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 53

Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016 54

Liver Fibrosis - Pipeline by KineMed, Inc., H2 2016 55

Liver Fibrosis - Pipeline by LG Life Science LTD., H2 2016 56

Liver Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016 57

Liver Fibrosis - Pipeline by Pfizer Inc., H2 2016 58

Liver Fibrosis - Pipeline by Pharmaxis Limited, H2 2016 59

Liver Fibrosis - Pipeline by Promedior, Inc., H2 2016 60

Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H2 2016 61

Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016 62

Liver Fibrosis - Pipeline by Ribomic Inc., H2 2016 63

Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 64

Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2016 65

Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2016 66

Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016 67

Liver Fibrosis - Pipeline by Virobay Inc., H2 2016 68

Liver Fibrosis - Pipeline by XTuit Pharmaceuticals, Inc., H2 2016 69

Assessment by Monotherapy Products, H2 2016 70

Assessment by Combination Products, H2 2016 71

Number of Products by Stage and Target, H2 2016 73

Number of Products by Stage and Mechanism of Action, H2 2016 77

Number of Products by Stage and Route of Administration, H2 2016 80

Number of Products by Stage and Molecule Type, H2 2016 82

Liver Fibrosis - Dormant Projects, H2 2016 184

Liver Fibrosis - Dormant Projects (Contd..1), H2 2016 185

Liver Fibrosis - Dormant Projects (Contd..2), H2 2016 186

Liver Fibrosis - Dormant Projects (Contd..3), H2 2016 187

Liver Fibrosis - Discontinued Products, H2 2016 188

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advinus Therapeutics Ltd

Akarna Therapeutics Ltd.

Angion Biomedica Corp.

Asubio Pharma Co., Ltd.

aTyr Pharma, Inc.

Beijing Kawin Technology Share-Holding Co., Ltd.

BioLineRx, Ltd.

Bioneer Corporation

BiOrion Technologies B.V.

Bird Rock Bio, Inc.

Bristol-Myers Squibb Company

Cellmid Limited

ContraVir Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

Dr. Falk Pharma GmbH

Dynavax Technologies Corporation

Evotec AG

Galectin Therapeutics, Inc.

Genfit SA

Gilead Sciences, Inc.

GNI Group Ltd.

HEC Pharm Co., Ltd.

Immuron Limited

Intercept Pharmaceuticals, Inc.

INVENT Pharmaceuticals, Inc.

Isarna Therapeutics GmbH

KineMed, Inc.

LG Life Science LTD.

Nitto Denko Corporation

Pfizer Inc.

Pharmaxis Limited

Promedior, Inc.

Promethera Biosciences S.A.

ProMetic Life Sciences Inc.

Ribomic Inc.

RXi Pharmaceuticals Corporation

Silence Therapeutics Plc

TCM Biotech International Corp

Vascular Biogenics Ltd.

Virobay Inc.

XTuit Pharmaceuticals, Inc.

Liver Fibrosis Therapeutic Products under Development, Key Players in Liver Fibrosis Therapeutics, Liver Fibrosis Pipeline Overview, Liver Fibrosis Pipeline, Liver Fibrosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 128960
Site License
USD 4000 INR 257920
Corporate User License
USD 6000 INR 386880

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com